
Xactagen LLC Profile last edited on: 1/21/13
CAGE: 4CXD4
UEI:
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: King
Congr. District: 07
County: King
Public Profile
Xactagen focuses its genetic engineering expertise on combining highly successful, physiology-based drug discovery with disease-relevant gene and protein data derived from genomics and proteomics. The resulting gene-specific, cell-based assays promise more productive and predictive drug discovery and development, allowing our company to play a significant role in bringing important new medicines to market
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2012 | 1 | NIH | $223,352 | |
Project Title: Innovative Approach For High-Volume Production Of Endogenous Reporter Cells | ||||
2007 | 1 | NIH | $100,000 | |
Project Title: HTS of Microglia for Clearance of Amyloid-Beta in Alzheimer's Disease |
Key People / Management
Robert E Finney -- President
Josef Peter Klein
Josef Peter Klein
Company News
There are no news available.